Sophiris Bio, Inc. (SPHS) Receives Consensus Recommendation of “Buy” from Analysts
Sophiris Bio, Inc. (NASDAQ:SPHS) has been assigned a consensus recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $6.60.
Several equities analysts have recently issued reports on the company. HC Wainwright set a $6.00 target price on Sophiris Bio and gave the stock a “buy” rating in a research report on Saturday, June 10th. Maxim Group set a $6.00 price target on Sophiris Bio and gave the company a “buy” rating in a research note on Thursday, June 8th. Finally, ValuEngine cut Sophiris Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, June 13th.
COPYRIGHT VIOLATION WARNING: “Sophiris Bio, Inc. (SPHS) Receives Consensus Recommendation of “Buy” from Analysts” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/04/sophiris-bio-inc-sphs-receives-consensus-recommendation-of-buy-from-analysts.html.
An institutional investor recently raised its position in Sophiris Bio stock. Vanguard Group Inc. boosted its position in shares of Sophiris Bio, Inc. (NASDAQ:SPHS) by 1.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 731,437 shares of the biopharmaceutical company’s stock after purchasing an additional 7,600 shares during the period. Vanguard Group Inc. owned about 2.43% of Sophiris Bio worth $1,609,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.01% of the company’s stock.
Sophiris Bio (SPHS) traded down 1.36% during mid-day trading on Wednesday, reaching $2.17. The company’s stock had a trading volume of 176,053 shares. The stock’s 50 day moving average is $2.12 and its 200 day moving average is $2.29. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $3.30. The company’s market cap is $65.34 million.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.